Selected Posters and Abstracts
Etravirine; aka TMC125
[Experimental NNRTI]
[PL5.2] TMC125 in combination with other medications: summary of drug-drug interaction studies
T N Kakuda and others.
[PL5.6] Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227
B Woodfall and others.
[P146] No frequent reporting of neurological or psychiatric events during TMC125 treatment
B Woodfall and others.
[P277] No effect of TMC125 on the pharmacokinetics of oral contraceptives
M Schöller-Gyüre and others.
[P278] Pharmacokinetics of TMC125, with atazanavir (ATV) and atazanavir/ritonavir (ATV/r)
M Schöller-Gyüre and others.
[P360] Emerging multi-drug resistance in children with perinatally acquired HIV-1
C Foster and others.
[P234] Adults with perinatally acquired HIV-1 infection: adherence, resistance and disease monitoring
C Foster and others.
 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada